Treatment of multiple sclerosis: Recent trials and future perspectives

Current Opinion in Neurology

Volumn 12, Issue 3, 1999, Pages 279-293

  Noseworthy, John H ^a   Gold, Ralf ^b   Hartung, Hans Peter ^c  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF WÜRZBURG   (Germany)

^c UNIVERSITY OF GRAZ   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 DIAMINOPYRIDINE; 4 AMINOPYRIDINE; ANTIBODY; AZATHIOPRINE; BETA INTERFERON; BETA1A INTERFERON; CELL ADHESION MOLECULE; CLADRIBINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYTOKINE; GABAPENTIN; GLATIRAMER; IMMUNOGLOBULIN; IMMUNOMODULATING AGENT; INTEGRIN; INTERFERON BETA SERINE; MATRIX METALLOPROTEINASE; METHYLPREDNISOLONE; MITOXANTRONE; MYELIN; MYLORAL; NATALIZUMAB; ONDANSETRON; SILDENAFIL; T LYMPHOCYTE RECEPTOR; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR RECEPTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG;

AUTOIMMUNE HEPATITIS; CLINICAL TRIAL; ERECTILE DYSFUNCTION; FEVER; HASHIMOTO DISEASE; HEADACHE; HERPES ZOSTER; HUMAN; IMMUNOTHERAPY; INFECTION; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY FAILURE; MALAISE; MENINGITIS; META ANALYSIS; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; ORAL DRUG ADMINISTRATION; RASH; REVIEW; SIDE EFFECT; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOSIS;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIVIRAL AGENTS; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOSUPPRESSIVE AGENTS; INTERFERONS; MULTIPLE SCLEROSIS;

EID: 0032794046     PISSN: 13507540     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019052-199906000-00007     Document Type: Review

References (127)

1. van den Noort S, Eidelman B, Rammohan K, et al. National Multiple Sclerosis Society (NMSS): Disease management consensus statement. New York, NY: National MS Society; 1998.
2. Rudick R, Goodkin D, Jacobs L, et al. Impact of interferon beta-1a on neurologic disability in relapsing multiple sclerosis. Neurology 1997; 49:358-363.
3. Simon J, Jacobs L, Campion M, et al. Magnetic resonance studies of intramuscular interferon β-1a for relapsing multiple sclerosis. Neurology 1998; 43:79-87. The authors of this study (and of [2]) present additional analyses on the impact of interferon-β-1a (Avonex) on disability progression and MRI evidence of disease activity in relapsing multiple sclerosis from the pivotal North American trial.
4. •]
5. •], leading experts present their opinions on the strength of evidence that interferons significantly effect multiple sclerosis disease activity. Many useful points are presented that will be of interest to the readership.
6. PRISMS (Prevention of Relapses and Disability by Interferon β-1a Subcutaneously in Multiple Sclerosis) Study Group. Randomised double-blind, placebo-controlled study of interferon beta-1a in relapsing-remitting multiple sclerosis. Lancet 1998; 352:1498-1504. The PRISMS trial provides corroborative evidence that interferon-β-1a (in this case, Rebif) reduces both clinical and MRI evidence of disease activity in relapsing-remitting multiple sclerosis. Of great interest, however, is the observation that higher doses of this agent than have been tested previously may provide additional beneficial effects on clinical evidence of disability progression. This finding suggests that the dose of interferon-β-1a approved for use in North America (Avonex) may be lower than required to provide optimal control of the disease.
7. European Study Group on Interferon beta-1b in secondary-progressive MS. Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. Lancet 1998; 352:1491-1497. This large phase III European trial demonstrates for the first time that interferon-β- 1b (Betaferon) slows clinical and MRI evidence of multiple sclerosis disease activity in secondary progressive patients. Of importance is their observation that interferon-β-1b was effective, regardless of the occurrence of recent or on-trial clinical relapse.
8. Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 1996; 39:285-294.
9. Li DKB, Paty UBC. MS/MRI Analysis research group and the PRISMS (Prevention of Relapses and Disability by Interferon-beta 1a Subcutaneously in Multiple Sclerosis) study group. Magnetic resonance imaging results of the PRISMS trial: A randomized, double blind, placebo-controlled study of interferon-beta 1a in relapsing-remitting multiple sclerosis. Ann Neurol 1999 (in press).
10. Freedman MS [for the Once Weekly Interferon for Multiple Sclerosis (OWIMS) Study Group]. Evidence of interieron-1a dose response in relapsing-remitting MS: The OWIMS study. Neurology (in press).
11. The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993; 43:655-661.
12. Johnson K, Brooks B, Cohen J, et al. Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Neurology 1998; 50:701-708.
13. Fazekas F, Deisenhammer F, Strasser-Fuchs S, Nahler G, Mamoli B, and the Austrian Immunoglobulin in MS Study Group. Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis. Lancet 1997; 349:589-593.
14. Khan O, Hebel J. Incidence of exacerbations in the first 90 days of treatment with recombinant human interferon beta-1b in patients with relapsing-remitting multiple sclerosis. Ann Neurol 1998; 44:138-139.
15. Calabresi P, Stone L, Bash C, Frank J, McFarland H. Interferon beta results in immediate reduction of contrast-enhanced MRI lesions in multiple sclerosis patients followed by weekly MRI. Neurology 1997; 48:1446-1448.
16. Durelli L, Bongioanni M, Ferrero B, Oggero A, Marzano A, Rizzetto M, Interferon treatment for multiple sclerosis: autoimmune complications may be lethal [letter]. Neurology 1998; 50:570.
17. Schwid SR, Goodman AD, Mattson DH Autoimmune hyperthyroidism in patients with multiple sclerosis treatment with interferon beta-1b. Arch Neurol 1997; 54:1169-1170.
18. Bramanti P, Sessa E, Rifici C, et al. Enhanced spasticity in primary progressive MS patients treated with interferon beta-1b. Neurology 1998; 51:1720-1723.
19. Johnson KP, Brooks BR, Cohen JA, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group [see comments]. Neurology 1995; 45:1268-1276.
20. Francis G, Freedman M, Antel J. Failure of intravenous immunoglobulin to arrest progression of multiple sclerosis: a clinical and MRI based study. Mult Scler 1997; 3:370-376.
21. •]
22. •] provide some evidence that IVIg reduces relapse rate (Israeli trial) and MRI activity (Danish trial) in relapsing-remitting multiple sclerosis.
23. Rodriguez M, Lennon VA, Benveniste EN, Merrill JE. Remyelination by oligodendrocytes stimulated by antiserum to spinal cord. J Neuropathol Exp Neurol 1987; 46:84-95.
24. Rodriguez M, Lennon VA. Immunoglobulins promote remyelination in the central nervous system, Ann Neurol 1990; 27:12-17.
25. Rodriguez M, Pierce ML, Thiemann RL. Immunoglobulins stimulate central nervous system remyelination: electron microscopic and morphometric analysis of proliferating cells. Lab Invest 1991; 64:358-370.
26. van Engelen BG, Hommes OR, Pinckers A, Cruysberg JR, Barkhof F, Rodriguez M. Improved vision after intravenous immunoglobulin in stable demyelinating optic neuritis [Letter]. Ann Neurol 1992; 32:834-835.
27. Noseworthy J, Weinshenker B, O'Brien P. Intravenous immunoglobulin (IVIg) does not reverse recently acquired, apparently permanent weakness in multiple sclerosis (MS) [abstract]. Ann Neurol 1997; 42:A421.
28. Noseworthy J, O'Brien P, Pettersen T, et al. Immunoglobulin administration (IVIg) does not reverse visual acuity loss in long-standing optic neuritis associated with multiple sclerosis. Ann Neurol 1998; 44:A504.
29. Stangel M, Compston A, Scolding NJ. Polyclonal immunoglobulins for intravenous use do not influence the behaviour of cultured oligodendrocytes. J Neuroimmunol 1999; 96:228-233.
30. Stangel M, Hartung HP, Marx P, Gold R. Intravenous immunoglobulin treatment of neurological autoimmune diseases. Clinical updates. J Neurol Sc 1998; 153:203-214.
31. Stangel M, Hartung HP, Marx P, Gold R. Side effects of high-dose intravenous immunoglobulins. Clin Neuropharmacol 1997; 29:385-393.
32. Lisak RP. Intravenous immunoglobulins in multiple sclerosis. Neurology 1998; 51 (Suppl 5):25-29.
33. Noseworthy J, O'Brien P, and the Mayo Clinic-Canadian Cooperative MS Study Group. The Mayo Clinic Canadian Cooperative Trial of Sulfasalazine in active multiple sclerosis. Neurology 1998; 51:1342-1352. This phase III trial demonstrates that drugs that favorably impact clinical and MRI markers of multiple sclerosis activity in the short term may not necessarily provide prolonged control of disease progression. The authors remind the readership that clinical trials in multiple sclerosis may need to be continued for at least 3 years before conclusions of efficacy can be considered to be definitive.
34. R) on disease activity as measured by cerebral MRI in patients with relapsing-remitting multiple sclerosis (RRMS): a multi-center, randomized, double-blind, placebo-controlled study extended by open-label treatment. Neurology 1999; 52 (Suppl 2):A289.
35. Rice G. Cladribine and chronic progressive multiple sclerosis: the results of a multicenter trial [abstract]. Neurology 1997; 48:1730.
36. Romine J, Sipe J, Koziol J, Zyroff J, Beutler E. A double-blind, placebo-controlled, randomized trial of Cladribine in relapsing-remitting multiple sclerosis. Proc Assoc Am Phys 1999; 111:35-44.
37. Weinstock-Guttman B, Kinkel R, Cohen J, et al. Treatment of fulminant multiple sclerosis with intravenous cyclophosphamide [abstract]. Neurologist 1997; 3:178-185.
38. Hauser SL, Dawson DM, Lehrich JR, et al. Intensive immunosuppression in progressive multiple sclerosis, A randomized, three-arm study of high-dose intravenous cyclophosphamide, plasma exchange, and ACTH. N Engl J Med 1983; 308:173-80.
39. Likosky WH, Fireman B, Elmore R, et al. Intense immunosuppression in chronic progressive multiple sclerosis: the Kaiser study. J Neurol Neurosurg Psychiatry 1991; 54:1055-1060.
40. The Canadian Cooperative Multiple Sclerosis Study Group. The Canadian cooperative trial of cyclophosphamide and plasma exchange in progressive multiple sclerosis. Lancet 1991; 337:441-446.
41. Noseworthy JH, Vandervoort MK, Penman M, et al. Cyclophosphamide and plasma exchange in multiple sclerosis. Lancet 1991; 337:1540-1541.
42. Hartung HP, Gonsette R and the MIMS-Study Group. Mitoxantrone in progressive multiple sclerosis (MS): a placebo-controlled, randomized, observer-blind European phase III multicenter study-clinical results. Mult Scler 1998; 4:325.
43. Krapf H, Morrissey SP, et al., and the MIMS-Study Group. Mitoxantrone in progressive multiple sclerosis (MS): a placebo-controlled, randomized, observer-blind European phase III multicenter study-MRI results. Mult Scler 1998; 4:380.
44. Francis G, Evans A, Panitch H. MRI results of a phase III trial of oral myelin in relapsing-remitting multiple sclerosis [abstract]. Ann Neurol 1997; 42:467.
45. Panitch H, Francis G, and the Oral Myelin Study Group. Clinical results of a phase III trial of oral myelin in relapsing-remitting multiple sclerosis [abstract]. Ann Neurol 1997; 42:459.
46. Kapoor R, Milter D, Jones S, et al. Effects of intravenous methylprednisolone on outcome in MRI-based prognostic subgroups in acute optic neuritis. Neurology 1998; 50:230-237.
47. Barnes D, Hughes R, Morris R, et al. Randomized trial of oral and intravenous methylprednisolone in acute relapses of multiple sclerosis. Lancet 1997; 349:902-906.
48. Tremlett H. Oral versus intravenous corticosteroids in acute relapses of multiple sclerosis. Lancet 1997; 349:1696-1697.
49. Reinhardt C, Reul J, Melms A. Oral versus intravenous corticosteroids in acute relapses of multiple sclerosis [letter]. Lancet 1997; 349:1698.
50. Barkof F, Polman C. Oral or intravenous methylprednisolone for acute relapse of MS? A Commentary. Lancet 1997; 349:893-894.
51. Oliveri RL, Valentino P, Russo C, et al. Randomized trial comparing two different high doses of methylprednisolone in MS. A clinical and MRI study. Neurology 1998; 50:1833-1836.
52. Tremlett H, Luscombe D, Wiles C. Use of corticosteroids in multiple sclerosis by consultant neurologists in the United Kingdom. J Neurol Neurosurg Psychiatry 1998;65:362-365.
53. Sheremata W, Vollmer T, Stone L, Willmer-Hulme A, Koller M. A safety and pharmacokinetic study of intravenous natalizumab in patients with MS. Neurology 1999; 55:1072-1074.
54. Burt RK, Burns WH, Miller SD. Bone marrow transplantation for multiple sclerosis: returning to Pandora's box. Immunol Today 1997; 18:559-561.
55. Krance R, Brenner M. BMT beats autoimmune disease. Nature Med 1998; 4:153-155.
56. Ikehara S. Bone marrow transplantation for autoimmune diseases. Acta Haematol 1998; 99:116-132.
57. Schwid S, Petrie M, McDermott M, Tierney D, Mason D, Goodman A. Quantitative assessment of sustained-release 4-aminopyridine for symptomatic treatment of multiple sclerosis. Neurology 1997; 48:817-821.
58. Kujihara K, Miyoshi T. The effects of 4-aminopyridine on motor evoked potentials in multiple sclerosis. J Neurol Sci 1998; 159:102-106.
59. Sheehan GL, Murray NMF, Rothwell JC, Miller DH, Thompson AJ. An open-labeled clinical and electrophysiological study of 3,4 diaminopyridine in the treatment of fatigue in multiple sclerosis. Brain 1998; 121:967-975.
60. Dunevsky A, Perel AB. Gabapentin for relief of spasticity associated with multiple sclerosis. Am J Phys Med Rehab 1998; 77:451-454.
61. Alusi SH, Glickman S, Aziz TZ, et al. Tremor in multiple sclerosis. J Neurol Neurosurg Psychiatry 1999; 66:131-134.
62. Rice GPA, Lesaux J, Vandervoort P, et al. Ondansetron, a 5-HT3 antagonist, improves cerebellar tremor. J Neurol Neurosurg Psychiatry 1997; 62:282-284.
63. Geny C, Nguyen JP, et al. Improvement of severe postural cerebellar tremor in multiple sclerosis by chronic thalamic stimulation. Mov Disord 1996; 11:489-494.
64. Whittle IR, Hooper J, et al. Thalamic deep-brain stimulation for movement disorders due to multiple sclerosis. Lancet 1998; 351:109-110.
65. Goldstein I, Lue TF, Padma NH, et al. Oral sildenafil in the treatment of erectile dysfunction. N Engl J Med 1998; 338:1397-1404.
66. Derry FA, Dinsmore WW, Fraser M, et al. Efficacy and safety of oral sildenafil (Viagra) in men with erectile dysfunction caused spinal cord injury. Neurol 1998; 51:1629-1633.
67. Maytom MC, Derry FA, Dinsmore WW, et al. A two-part pilot study of sildenafil (Viagra™) in men with erectile dysfunction caused by spinal cord injury. Spinal Cord 1993; 37:110-116.
68. Storch MK, Stefferl A, Brehm U, et al. Autoimmunity to myelin oligodendrocyte glycoprotein in rats mimics the spectrum of multiple sclerosis pathology. Brain Pathol 1998, 8:681-694. This paper supports the strong role of myelin oligodendrocyte glycoprotein in the pathogenesis of disease and further corroborates the pathogenetic relevance of myelin oligodendrocyte glycoprotein.
69. Lucchinetti CF, Brück W, Rodriguez M, Lassmann H. Distinct patterns of multiple sclerosis pathology indicates heterogeneity in pathogenesis. Brain Pathol 1996; 6:259-274.
70. Genain CP, Cannella B, Hauser SL, Raine CS. Identification of autoantibodies associated with myelin damage in multiple sclerosis. Nature Med 1999; 5:170-175. This paper gives evidence for specific binding of anti-myelin oligodendrocyte glycoprotein antibodies in brain tissue from multiple sclerosis patients - strong support for experimental concepts coined in EAE is provided.
71. Berger T, Weerth S, Kojima K, et al. Experimental autoimmune encephalomyelitis: the antigen specificity of T lymphocytes determines the topography of lesions in the central and peripheral nervous system. Lab Invest 1997; 76:355-364.
72. Weissert R, Wallström E, Storch MK, et al. MHC haplotype-dependent regulation of MOG-induced EAE in rats. J Clin Invest 1998; 102:1265-1273. Elegant work that delineates a stepwise increase in susceptibility to EAE depending on major histocompatibility complex class II genes, other major histocompatibility complex genes, and genes outside the major histocompatibility complex.
73. Liblau R, Tisch R, Bercovici N, McDevitt HO. Systemic antigen in the treatment of T-cell-mediated autoimmune diseases. Immunol Today 1997; 18:599-604.
74. Hemmer B, Vergelli M, Pinilla C, Houghten R, Martin R. Probing degeneracy in T-cell recognition using peptide combinatorial libraries. Immunol Today 1998; 19:163-168. Sophisticated molecular biochemistry that reflects the state of the art concerning mutation of peptide ligands.
75. Gold R, Harlung HP, Lassmann H. T-cell apoptosis in autoimmune diseases: termination of inflammation in the nervous system and other sites with specialized immune-defense mechanisms. Trends Neurosci 1997; 20:399-404.
76. Ben-Nun A, Wekerle H, Cohen IR. Vaccination against autoimmune encephalomyelitis with T-lymphocyte line cells reactive against myelin basic protein. Nature 1981; 292:60-61.
77. Vandenbark AA, Chou YK, Whitham R, et al. Treatment of multiple sclerosis with T-cell receptor peptides: results of a double-blind pilot trial. Nature Med 1996; 2:1109-1115.
78. Hafler DA, Saadeh MG, Kuchroo VK, Milford E, Steinman L. TCR usage in human and experimental demyelinating disease. Immunol Today 1996; 17:152-159.
79. Hemmer B, Vergelli M, Tranquill L, et al. Human T-cell response to myelin basic protein peptide (83-99): extensive heterogeneity in antigen recognition, function, and phenotype. Neurology 1997; 49:1116-1126.
80. Meinl E, Weber F, Drexler K, et al. Myelin basic protein-specific T lymphocyte repertoire in multiple sclerosis. Complexity of the response and dominance of nested epitopes due to recruitment of multiple T cell clones. J Clin Invest 1993; 92:2633-2643.
81. Vandenbark AA, Hashim GA, Offner H. T cell receptor peptides in treatment of autoimmune disease: rationale and potential. J Neurosci Res 1996; 43:391-402.
82. Sloan Lancaster J, Allen PM. Altered peptide ligand-induced partial T cell activation: molecular mechanisms and role in T cell biology. Annu Rev Immunol 1996; 14:1-27.
83. Windhagen A, Scholz C, Hollsberg P, et al. Modulation of cytokine patterns of human autoreactive T cell clones by a single amino acid substitution of their peptide ligand. Immunity 1995; 2:37-380.
84. Nicholson LB, Greer JM, Sobel RA, Lees MB, Kuchroo VK. An altered peptide ligand mediates immune deviation and prevents autoimmune encephalomyelitis. Immunity 1995; 3:397-405.
85. Aharoni R, Teitelbaum D, Arnon R, et al. Copolymer 1 acts against the immunodominant epitope 82-100 of myelin basic protein by T cell receptor antagonism in addition to major histocompatibility complex blocking. Proc Natl Acad Sci U S A 1999; 96:634-639.
86. Lindsey JW, Lublin FD, Stark SR, et al. Double-blind, randomized, placebo-controlled evaluation of the safety, tolerability, and pharmacokinetics of CGP 77116 in patients with multiple sclerosis (abstract). Neurology 1998; 50:A139.
87. Critchfield JM, Racke MK, Zuniga Pflucker JC, et al. T cell deletion in high antigen dose therapy of autoimmune encephalomyelitis. Science 1994; 263:1139-1143.
88. Elliott EA, McFarland HI, Nye SH, et al. Treatment of experimental encephalomyelitis with a novel chimeric fusion protein of myelin basic protein and proteolipid protein. J Clin Invest 1996; 98:1602-1612.
89. Schluesener HJ. Protection against generalized autoimmunity of the nervous system (GANS), a novel animal model with combined features of EAE, EAN and EAU by a recombinant HIV-1 Tat37-72 peptide-based multiple T cell epitope vaccine. FEMS Immunol Med Microbiol 1997; 17:179-186.
90. Weishaupt A, Gold R, Giegerich G, Hartung H-P, Toyka KV. Antigen therapy eliminates T-cell inflammation by apoptosis: effective treatment of experimental autoimmune neuritis with recombinant myelin protein P2. Proc Natl Acad Sci U S A 1997; 94:1338-1342.
91. Zettl UK, Gold R, Toyka KV, Hartung HP. Intravenous glucocorticosteroid treatment augments apoptosis of inflammatory T cells in experimental autoimmune neuritis (EAN) of the Lewis rat. J Neuropathol Exp Neurol 1995; 54:540-547.
92. Weiner HL, Friedman A, Miller A, et al. Oral tolerance: immunologic mechanisms and treatment of animal and human organ-specific autoimmune diseases by oral administration of autoantigens. Ann Rev Immunol 1994; 12:809-837.
93. Chen YH, Inobe J, Kuchroo VK, et al. Oral tolerance in myelin basic protein T-cell receptor transgenic mice: suppression of autoimmune encephalomyelitis and dose-dependent induction of regulatory cells. Proc Nat Acad Sci U S A 1996; 93:388-391.
94. Barnett ML, Kremer JM, St Clair EW, et al. Treatment of rheumatoid arthritis with oral type II collagen-results of a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum 1998; 41:290-297.
95. Brod SA, Khan M, Kerman RH, Pappolla M. Oral administration of human or murine interferon alpha suppresses relapses and modifies adoptive transfer in experimental autoimmune encephalomyelitis. J Neuroimmunol 1995; 58:61-69.
96. Teitelbaum D, Arnon R, Sela M. Immunomodulation of experimental autoimmune encephalomyelitis by oral administration of copolymer-1. Proc Natl Acad Sci U S A 1999; 96:3842-3847.
97. Greenfield EA, Nguyen KA, Kuchroo VK. CD28/B7 costimulation: a review. Crit Rev Immunol 1998; 18: 389-418. Complete illustration of the biologic importance of the CD28/B7 costimulatory system is provided.
98. Karandikar NJ, Vanderlugt CL, Bluestone JA, Miller SD. Targeting the B7/ CD28:CTLA-4 costimulatory system in CNS autoimmune disease. J Neuroimmunol 1998; 89:10-18.
99. Arima T, Rehman A, Hickey WF, Flye MW. Inhibition by CTLA4lg of experimental allergic encephalomyelitis. J Immunol 1996; 156:4916-4924.
100. Hurwitz AA, Sullivan TJ, Krummel MF, Sobel RA, Allison JP. Specific blockade of CTLA-4/B7 interactions results in exacerbated clinical and histologic disease in an actively-induced model of experimental allergic encephalomyelitis. J Neuroimmunol 1997; 73:57-62.
101. Lovett-Racke AE, Trotter JL, Lauber J, et al. Decreased dependence of myelin basic protein-reactive T cells on CD28-mediated costimulation in multiple sclerosis patients-a marker of activated/memory T cells. J Clin Invest 1998; 101:725-730.
102. Tacke M, Hanke G, Hanke T, Hünig T. CD28-mediated induction of proliferation in resting T cells in vitro and in vivo without engagement of the T cell receptor: evidence for functionally distinct forms of CD28. Eur J Immunol 1997; 27:239-247. This is the first evidence that ligation of CD28 may result in qualitatively different cellular responses.
103. Grewal IS, Flavell RA. CD40 and CD154 in cell-mediated immunity. Annu Rev Immunol 1998; 16:111-135. This review focuses on the role of CD40/CD40L in the regulation of many functions important in cell-mediated immunity.
104. Grewal IS, Foellmer HG, Grewal KD, et al. Requirement for CD40 ligand in costimulation induction, T cell activation, and experimental allergic encephalomyelitis. Science 1996; 273:1864-1867.
105. Howard LM, Miga AJ, Vanderlugt CL, et al. Mechanisms of immunother-apeutic intervention by anti-CD40L (CD154) antibody in an animal model of multiple sclerosis. J Clin Invest 1999; 103:281-290.
106. Jung S, Toyka K, Hartung HP. Suppression of experimental autoimmune encephalomyelitis in Lewis rats by antibodies against CD2. Eur J Immunol 1995; 25:1391-1398.
107. Archelos JJ, Hartung H-P. The role of adhesion molecules in multiple sclerosis: biology, pathogenesis and therapeutic implications. Mol Med Today 1997; 3:310-321.
108. Yednock TA, Cannon C, Fritz LC, et al. Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha4beta1 integrin. Nature 1992; 356:63-66.
109. Archelos JJ, Jung S, Rinner W, et al. Role of the leukocyte-adhesion molecule L-selectin in experimental autoimmune encephalomyelitis. J Neurol Sci 1998; 159:127-134.
110. Hartung HP, Reiners K, Archelos JJ, et al. Circulating adhesion molecules and tumor necrosis factor receptor in multiple sclerosis: correlation with magnetic resonance imaging. Ann Neurol 1995; 38:186-193.
111. Cannella B, Raine CS. The adhesion molecule and cytokine profile of multiple sclerosis lesions [see comments]. Ann Neurol 1995; 37:424-435.
112. Archelos JJ, Jung S, Maurer M, et al. Inhibition of experimental autoimmune encephalomyelitis by an antibody to the intercellular adhesion molecule ICAM-1. Ann Neurol 1993; 34:145-154.
113. Chandler S, Miller KM, Clements JM, et al. Matrix metalloproteinases, tumor necrosis factor and multiple sclerosis: an overview. J Neuroimmunol 1997; 72:155-161.
114. Kieseier BC, Seifert T, Giovannoni G, Hartung HP. Matrix metalloproteinases in inflammatory demyelinalion-targets for treatment. Neurology 1999 (in press).
115. Liedtke W, Cannella B, Mazzaccaro RJ, et al. Effective treatment of models of multiple sclerosis by matrix metalloproteinase inhibitors. Ann Neurol 1998; 44:35-46. Illustration of therapeutic relevance of rnetalloproteinase inhibition in EAE.
116. Selmaj K, Raine CS. Tumor necrosis factor mediates myelin and oligodendrocyte damage in vitro. Ann Neurol 1988; 23:339-346.
117. Selmaj K, Raine CS, Cross AH. Anti-tumor necrosis factor therapy abrogates autoimmune demyelination. Ann Neurol 1991; 30:694-700.
118. Liu JL, Marino MW, Wong G, et al. TNF is a potent anti-inflammatory cytokine in autoimmune-mediated demyelination. Nature Med 1998; 4:78-83.
119. Eugster HP, Frei K, Bachmann R, et al. Severity of symptoms and demyelinationin MOG-induced EAE depends on TNFR1. Eur J Immunol 1999; 29:626-632. This paper lends further support to the pivotal role that TNF and its receptors have in central nervous system inflammation. Signaling through TNFR2 contributes to termination of inflammation.
120. Jung S, Zielasek J, Köllner G, et al. Preventive but not therapeutic application of Rolipram ameliorates experimental autoimmune encephalomyelitis in Lewis rats. J Neuroimmunol 1996; 68:1-11.
121. Sommer N, Martin R, McFarland HF, et al. Therapeutic potential of phosphodiesterase type 4 inhibition in chronic autoimmune demyelinating disease. J Neuroimmunol 1997; 79:54-61.
122. Van Oosten BW, Barkhof F, Truyen L, et al. Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2. Neurology 1996; 47:1531-1534.
123. Weinblatt ME, Kremer JM, Bankhurst AD, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999; 340:253-259.
124. Calabresi PA, Fields NS, Maloni HW, et al. Phase 1 trial of transforming growth factor beta 2 in chronic progressive MS. Neurology 1998; 51:289-292.
125. Sallusto F, Lanzavecchia A, Mackay CR. Chemokines and chemokine receptors in T-cell priming and Th1/Th2-mediated responses. Immunol Today 1998; 19:568-574.
126. Zlotnik A, Morales J, Hedrick JA. Recent advances in chemokines and chemokine receptors. Crit Rev Immunol 1999; 19:1-47.
127. Youssef S, Wildbaum G, Maor G, et al. Long-lasting protective immunity to experimental autoimmune encephalomyelitis following vaccination with naked DNA encoding C-C chemokines. J Immunol 1998; 161:3870-3879.